This content requires an NEJM.org account. Create a free account now. Already have an account? Sign in .

Quick Take Free Preview

Phase 1–2 Trial of Gene Therapy for Hemophilia B

Continue to access content

Select an option below:

This content requires an account.

Create Account

Already have an account?

Sign In

Hemophilia B is a bleeding disorder caused by mutations in the F9 gene that lead to low clotting factor IX levels. Gene therapy to restore factor IX levels might provide long-term treatment. New research findings are summarized in a short video.

This content requires an NEJM.org account.

Create Account